Samsung Biologics Co Ltd
KRX:207940
Operating Margin
Samsung Biologics Co Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | KR |
Market Cap | 55.6T KRW |
Operating Margin |
30%
|
Country | US |
Market Cap | 230B USD |
Operating Margin |
17%
|
Country | US |
Market Cap | 192B USD |
Operating Margin |
22%
|
Country | US |
Market Cap | 44.3B USD |
Operating Margin |
19%
|
Country | US |
Market Cap | 42B USD |
Operating Margin |
14%
|
Country | CH |
Market Cap | 37.4B CHF |
Operating Margin |
20%
|
Country | US |
Market Cap | 32B USD |
Operating Margin |
29%
|
Country | IE |
Market Cap | 26.1B USD |
Operating Margin |
13%
|
Country | US |
Market Cap | 25.9B USD |
Operating Margin |
23%
|
Country | US |
Market Cap | 21.3B USD |
Operating Margin |
27%
|
Country | FR |
Market Cap | 19.3B EUR |
Operating Margin |
15%
|
Profitability Report
View the profitability report to see the full profitability analysis for Samsung Biologics Co Ltd.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Samsung Biologics Co Ltd's most recent financial statements, the company has Operating Margin of 30.1%.